Literature DB >> 28473526

Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Yi-Feng Gu1,2, Shannon Cohn1,2, Alana Christie2, Tiffani McKenzie2,3, Nicholas Wolff1,2, Quyen N Do4, Ananth J Madhuranthakam4, Ivan Pedrosa2,4, Tao Wang2,5, Anwesha Dey6, Meinrad Busslinger7, Xian-Jin Xie2,8, Robert E Hammer9, Renée M McKay1,2, Payal Kapur10,3, James Brugarolas11,2.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by BAP1 and PBRM1 mutations, which are associated with tumors of different grade and prognosis. However, whether BAP1 and PBRM1 loss causes ccRCC and determines tumor grade is unclear. We conditionally targeted Bap1 and Pbrm1 (with Vhl) in the mouse using several Cre drivers. Sglt2 and Villin proximal convoluted tubule drivers failed to cause tumorigenesis, challenging the conventional notion of ccRCC origins. In contrast, targeting with PAX8, a transcription factor frequently overexpressed in ccRCC, led to ccRCC of different grades. Bap1-deficient tumors were of high grade and showed greater mTORC1 activation than Pbrm1-deficient tumors, which exhibited longer latency. Disrupting one allele of the mTORC1 negative regulator, Tsc1, in Pbrm1-deficient kidneys triggered higher grade ccRCC. This study establishes Bap1 and Pbrm1 as lineage-specific drivers of ccRCC and histologic grade, implicates mTORC1 as a tumor grade rheostat, and suggests that ccRCCs arise from Bowman capsule cells.Significance: Determinants of tumor grade and aggressiveness across cancer types are poorly understood. Using ccRCC as a model, we show that Bap1 and Pbrm1 loss drives tumor grade. Furthermore, we show that the conversion from low grade to high grade can be promoted by activation of mTORC1. Cancer Discov; 7(8); 900-17. ©2017 AACR.See related commentary by Leung and Kim, p. 802This article is highlighted in the In This Issue feature, p. 783. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28473526      PMCID: PMC5540776          DOI: 10.1158/2159-8290.CD-17-0292

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  63 in total

1.  Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice.

Authors:  J R Gnarra; J M Ward; F D Porter; J R Wagner; D E Devor; A Grinberg; M R Emmert-Buck; H Westphal; R D Klausner; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

3.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Loss of the tumor suppressor BAP1 causes myeloid transformation.

Authors:  Anwesha Dey; Dhaya Seshasayee; Rajkumar Noubade; Dorothy M French; Jinfeng Liu; Mira S Chaurushiya; Donald S Kirkpatrick; Victoria C Pham; Jennie R Lill; Corey E Bakalarski; Jiansheng Wu; Lilian Phu; Paula Katavolos; Lindsay M LaFave; Omar Abdel-Wahab; Zora Modrusan; Somasekar Seshagiri; Ken Dong; Zhonghua Lin; Mercedesz Balazs; Rowena Suriben; Kim Newton; Sarah Hymowitz; Guillermo Garcia-Manero; Flavius Martin; Ross L Levine; Vishva M Dixit
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

5.  The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Authors:  Amrita M Nargund; Can G Pham; Yiyu Dong; Patricia I Wang; Hatice U Osmangeyoglu; Yuchen Xie; Omer Aras; Song Han; Toshinao Oyama; Shugaku Takeda; Chelsea E Ray; Zhenghong Dong; Mathieu Berge; A Ari Hakimi; Sebastien Monette; Carl L Lekaye; Jason A Koutcher; Christina S Leslie; Chad J Creighton; Nils Weinhold; William Lee; Satish K Tickoo; Zhong Wang; Emily H Cheng; James J Hsieh
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

Review 6.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

7.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

Authors:  Payal Kapur; Samuel Peña-Llopis; Alana Christie; Leah Zhrebker; Andrea Pavía-Jiménez; W Kimryn Rathmell; Xian-Jin Xie; James Brugarolas
Journal:  Lancet Oncol       Date:  2013-01-16       Impact factor: 41.316

8.  The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.

Authors:  Salima Daou; Ian Hammond-Martel; Nazar Mashtalir; Haithem Barbour; Jessica Gagnon; Nicholas V G Iannantuono; Nadine Sen Nkwe; Alena Motorina; Helen Pak; Helen Yu; Hugo Wurtele; Eric Milot; Frédérick A Mallette; Michele Carbone; El Bachir Affar
Journal:  J Biol Chem       Date:  2015-09-28       Impact factor: 5.157

9.  Of mice and men: divergence of gene expression patterns in kidney.

Authors:  Lydie Cheval; Fabien Pierrat; Rabary Rajerison; David Piquemal; Alain Doucet
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

10.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

View more
  55 in total

1.  An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Authors:  Rong Lu; Payal Kapur; Bijay S Jaiswal; Tao Wang; Raquibul Hannan; Ze Zhang; Ivan Pedrosa; Jason J Luke; He Zhang; Leonard D Goldstein; Qurratulain Yousuf; Yi-Feng Gu; Tiffani McKenzie; Allison Joyce; Min S Kim; Xinlei Wang; Danni Luo; Oreoluwa Onabolu; Christina Stevens; Zhiqun Xie; Mingyi Chen; Alexander Filatenkov; Jose Torrealba; Xin Luo; Wenbin Guo; Jingxuan He; Eric Stawiski; Zora Modrusan; Steffen Durinck; Somasekar Seshagiri; James Brugarolas
Journal:  Cancer Discov       Date:  2018-06-08       Impact factor: 39.397

2.  Kidney cancer: Bap1 and Pbrm1 determine tumour grade.

Authors:  Peter Sidaway
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

Review 3.  The HIF and other quandaries in VHL disease.

Authors:  D Tarade; M Ohh
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

Review 4.  Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Authors:  Michele Carbone; Ivano Amelio; El Bachir Affar; James Brugarolas; Lisa A Cannon-Albright; Lewis C Cantley; Webster K Cavenee; Zhijian Chen; Carlo M Croce; Alan D' Andrea; David Gandara; Carlotta Giorgi; Wei Jia; Qing Lan; Tak Wah Mak; James L Manley; Katsuhiko Mikoshiba; Jose N Onuchic; Harvey I Pass; Paolo Pinton; Carol Prives; Nathaniel Rothman; Said M Sebti; James Turkson; Xifeng Wu; Haining Yang; Herbert Yu; Gerry Melino
Journal:  Cell Death Differ       Date:  2018-10-15       Impact factor: 15.828

5.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.

Authors:  Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

Review 6.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

7.  Bap1 and Pbrm1: Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma.

Authors:  Janet Y Leung; William Y Kim
Journal:  Cancer Discov       Date:  2017-08       Impact factor: 39.397

Review 8.  The SWI/SNF complex in cancer - biology, biomarkers and therapy.

Authors:  Priya Mittal; Charles W M Roberts
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

Review 9.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

Review 10.  Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.

Authors:  James J Hsieh; Valerie H Le; Toshinao Oyama; Christopher J Ricketts; Thai Huu Ho; Emily H Cheng
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.